FOXP3 and neoplasm: Further, systemic depletion of Foxp3+ Tregs enhances natural as well as vaccine-induced anti-tumor T cell responses (Liyanage et al., 2002; Curiel et al., 2004; Dannull et al., 2005; Miller et al., 2006), as does targeting CD11b+ myeloid cells (Ahn et al., 2010).